Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 2 de 2
Filter
Add more filters











Database
Language
Publication year range
1.
Genet Mol Res ; 15(4)2016 Nov 21.
Article in English | MEDLINE | ID: mdl-27886329

ABSTRACT

The -251A/T polymorphism in the anti-inflammatory cytokine interleukin-8 (IL-8) gene has been implicated in susceptibility to periodontitis; however, this correlation has not been elucidated. In this meta-analysis, we investigated the association between the IL-8 -251A/T polymorphism and the risk of periodontitis. All eligible case-control studies published until August 2014 were identified and extracted from PubMed, Web of Science, EMBASE, China National Knowledge Internet, and WanFang databases. The strength of this association was accessed by pooled odds ratios (ORs) with 95% confidence intervals (CIs), using either a fixed- or random-effect model. Nine case-control studies, including 1811 cases and 2043 controls, were identified. Overall, no significant associations were found between the IL-8 -251A/T polymorphism and the risk of periodontitis. The results of the analysis of periodontitis subgroup revealed similarities between chronic periodontitis and aggressive periodontitis. An additional analysis based on ethnicity revealed an association between the IL-8 -251A/T polymorphism and periodontitis among Asians (dominant model, OR = 1.784, 95%CI = 1.130-2.817) and a mixed population (AA vs TT, OR = 0.667, 95%CI = 0.471-0.974). The results of this meta-analysis suggest that the IL-8 -251A/T polymorphism may increase the risk of periodontitis in Asian and mixed populations. However, larger and well-designed studies are warranted to validate our findings.


Subject(s)
Chronic Periodontitis/genetics , Interleukin-8/genetics , Polymorphism, Single Nucleotide , Asian People/genetics , Chronic Periodontitis/ethnology , Genetic Predisposition to Disease , Humans
2.
Clin Transl Oncol ; 18(2): 178-88, 2016 Feb.
Article in English | MEDLINE | ID: mdl-26184726

ABSTRACT

PURPOSE: Elevated plasma fibrinogen and D-dimer levels indicate activation of hemostasis and fibrinolysis, and this activation is required for tumor angiogenesis, metastasis, and invasion. Previous studies demonstrated that the plasma fibrinogen and D-dimer levels correlate with patient's prognosis in several solid tumors. The aim of this study is to examine the relationship between plasma fibrinogen and D-dimer levels before and during chemotherapy and treatment response and survival in patients with small cell lung cancer (SCLC). METHODS: Plasma fibrinogen and D-dimer levels before and during chemotherapy were prospectively measured in 74 SCLC patients who received first-line therapy. The results were analyzed for correlation between fibrinogen and D-dimer levels and treatment response, as well as progressive-free survival (PFS) and overall survival (OS). RESULTS: The levels of fibrinogen and D-dimer in SCLC patients before (C0) and after two cycles (C2) of chemotherapy were significantly higher than those in controls. Fibrinogen and D-dimer levels decreased during chemotherapy, and changes in fibrinogen and D-dimer levels between at C0 and at C2 were associated with treatment response. No matter which disease stage, patients with fibrinogen or D-dimer positivities at C0 and C2 time points had worse PFS and OS than those with fibrinogen or D-dimer negativities. Multivariate analyses revealed that fibrinogen and D-dimer positivities after two chemotherapy cycles were independently unfavorable factors for PFS and OS. CONCLUSION: Fibrinogen and D-dimer levels after two cycles of chemotherapy are predictors for response on chemotherapy and prognosis in SCLC patients.


Subject(s)
Biomarkers, Tumor/blood , Fibrin Fibrinogen Degradation Products/metabolism , Fibrinogen/metabolism , Lung Neoplasms/blood , Small Cell Lung Carcinoma/blood , Adult , Aged , Aged, 80 and over , Antineoplastic Combined Chemotherapy Protocols/therapeutic use , Cisplatin/administration & dosage , Disease-Free Survival , Drug Resistance, Neoplasm/physiology , Etoposide/administration & dosage , Female , Fibrin Fibrinogen Degradation Products/analysis , Fibrinogen/analysis , Humans , Immunoassay , Kaplan-Meier Estimate , Lung Neoplasms/drug therapy , Lung Neoplasms/mortality , Male , Middle Aged , Prognosis , Proportional Hazards Models , Prospective Studies , Small Cell Lung Carcinoma/drug therapy , Small Cell Lung Carcinoma/mortality
SELECTION OF CITATIONS
SEARCH DETAIL